RxDoctor Payments Data

Alexander Duarte, MD

Pulmonary Disease · Galveston, TXNPI 1780744730

Payments from drug & device makers

$114,737in general payments, 2019–2025

Across 469 payments — averaging $244.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Roche Products Limited$60K
  • Insmed, Inc.$50K
  • Boehringer Ingelheim International GmbH$4K
  • Actelion Pharmaceuticals US, Inc.$194
  • United Therapeutics Corporation$109
  • Pulmonx Corporation$47
  • plus $63 from 3 others

What the payments were for

  • Consulting fees$1,57521%
  • Speaking & faculty fees$4,05055%
  • Travel & lodging$85612%
  • Food & beverage$79511%
  • Education$921%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$114,737 in reported general payments places this provider in the 90th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$46,956
Medicare patients
287
Services billed
635

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ambrisentan81$328,809
LetairisAmbrisentan13$173,312
OfevNintedanib Esylate12$153,764
OpsumitMacitentan11$135,409
Trelegy ElliptaFluticasone/Umeclidin/Vilanter92$67,606
AdcircaTadalafil11$43,485
Dupixent PenDupilumab11$41,891
Stiolto RespimatTiotropium Br/Olodaterol Hcl65$33,804
Spiriva RespimatTiotropium Bromide37$31,320
Tadalafil21$16,179
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$12,480
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$12,285
SymbicortBudesonide/Formoterol Fumarate27$8,426
Spiriva HandihalerTiotropium Bromide15$7,506
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$4,997

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit$194$135,40911 claims
United Therapeutics CorporationAdcirca$109$43,48511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Galveston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →